Sierra Oncology, Inc.
https://www.sierraoncology.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sierra Oncology, Inc.
Keeping Track: US FDA Okays Alnylam’s siRNA Amvuttra, Alopecia Claim For Lilly’s Olumiant; Sierra Submits Momelotinib
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
GSK Gets A Lucky Q1 Boost, But All Eyes Are On RSV Vaccine Readout
GlaxoSmithKline has just acquired a late-stage oncology asset, and sales of Shingrix are on the up again, but the outcome of its RSV vaccine study remains the main focus for 2022.
As Biotech M&A Activity Gingerly Rises, Regeneron Makes Moves On Checkmate
Regeneron hopes to bolster its immuno-oncology pipeline with the acquisition of Checkmate, which joins a spate of similar deals suggesting renewed interest in biotech investment despite an industry-wide slowdown.
Another New Home For Momelotinib As GSK Buys Sierra
GlaxoSmithKline is paying a 39% premium to buy Sierra Oncology and its myelofibrosis therapy momelotinib which is set to be filed shortly in the US on the back of a strong Phase III package.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
- Liposomes
- Other Names / Subsidiaries
-
- ProNAi Therapeutics, Inc.